


Q1 In order of most value add please rank your top 3 choices of the following educational topics:


Answered: 18 Skipped: 0



	1	2	3	4	5	6	7	TOTAL	SCORE
Next Generation Sequencing	25.00% 1	0.00% 0	25.00% 1	0.00% 0	0.00% 0	25.00% 1	25.00% 1	4	3.75
Whole Genome Sequencing	16.67% 1	33.33% 2	33.33% 2	0.00% 0	0.00% 0	16.67% 1	0.00% 0	6	5.17
Pharmacogenomics	33.33% 3	33.33% 3	11.11% 1	11.11% 1	11.11% 1	0.00% 0	0.00% 0	9	5.67
Pharmacogenetics	37.50% 3	37.50% 3	0.00% 0	12.50% 1	12.50% 1	0.00% 0	0.00% 0	8	5.75
Data Privacy and Sharing	23.08% 3	30.77% 4	46.15% 6	0.00% 0	0.00% 0	0.00% 0	0.00% 0	13	5.77
Data use in Clinical Trials	9.09% 1	36.36% 4	45.45% 5	0.00% 0	0.00% 0	0.00% 0	9.09% 1	11	5.18
Why undefined future research is important to clinical trials	54.55% 6	18.18% 2	27.27% 3	0.00% 0	0.00% 0	0.00% 0	0.00% 0	11	6.27

Q2 In order of most value add please rank the following formats that could be used for future education materials?

Answered: 16 Skipped: 2



	1	2	3	4	5	6	TOTAL	SCORE
Webinar presentation	42.86% 6	21.43% 3	7.14% 1	7.14% 1	14.29% 2	7.14% 1	14	4.50
Videos	42.86% 6	21.43% 3	14.29% 2	14.29% 2	0.00% 0	7.14% 1	14	4.71
Journal articles	0.00% 0	30.00% 3	20.00% 2	10.00% 1	20.00% 2	20.00% 2	10	3.20
Brochures	18.18% 2	0.00% 0	45.45% 5	9.09% 1	27.27% 3	0.00% 0	11	3.73
One page reference guides	8.33% 1	25.00% 3	33.33% 4	25.00% 3	0.00% 0	8.33% 1	12	3.92
Online Powerpoints	8.33% 1	33.33% 4	16.67% 2	8.33% 1	8.33% 1	25.00% 3	12	3.50


Q3 Are there any other types of formats (not mentioned in Question 2) that you would suggest for future education materials?

Answered: 11 Skipped: 7

#	RESPONSES	DATE
1	No	8/21/2018 2:18 PM
2	No	8/17/2018 2:32 PM
3	None	8/16/2018 8:36 PM
4	It's unclear to me who the intended audience is for these materials (IRBs/ECs, study participants, clinical trial site staff, someone else?), so it's hard to answer the questions.	8/16/2018 7:36 PM
5	No	8/16/2018 5:17 PM
6	Links to relevant websites.	8/14/2018 3:10 PM
7	NA	8/8/2018 2:43 PM
8	NA	8/7/2018 2:09 AM
9	Conference presentations	8/6/2018 3:29 PM
10	Presence and presentations in scientific meetings	8/6/2018 2:46 PM
11	dedicated website with forum	8/6/2018 12:09 PM

Q4 Does your company have education needs that could be supported by the Education & Communication Task Force?

Answered: 17 Skipped: 1



ANSWER CHOICES	RESPONSES	
Yes	41.18%	7
No	58.82%	10
TOTAL		17

Q5 If you answered "Yes" to Question 4 please describe what materials could be useful?

Answered: 9 Skipped: 9

#	RESPONSES	DATE
1	Video or brochure	8/21/2018 2:18 PM
2	Online powerpoint presentations	8/20/2018 4:15 PM
3	To clarify the "No" response to #4, I think most IRBs/ECs are pretty well versed. As for study participants, since these topics are often not the main focus of the trial, there needs to be a balance between 1) having subjects who understand pharmacogenomics very well and 2) keeping the consent process as short as possible and giving the most focus to the key aspects of the trial. It seems disproportionate to spend a lot of time on this one particular aspect of a trial. Patient advocacy groups can be influential and may be a new group to reach out to. Otherwise, I don't feel there is much value to producing more educational materials at this time.	8/16/2018 7:36 PM
4	Patient video will be very useful. Have a need for basic information on why we request samples for future research and how we will try to keep patient data confidential. Format - Video or one-pager	8/16/2018 5:17 PM
5	Webinars or short, concise documents that could be shared electronically would be useful.	8/14/2018 3:10 PM
6	Summaries of the global regulations around PGx assessments in trial would be useful.	8/8/2018 2:43 PM
7	NA	8/7/2018 2:09 AM
8	Lay summaries regarding how we use genetic data in clinical trials	8/6/2018 3:29 PM
9	Video for educating	8/6/2018 2:33 PM


Q6 Are there other educational materials that you think would be useful in developing?

Answered: 11 Skipped: 7

#	RESPONSES	DATE
1	No	8/21/2018 2:18 PM
2	No	8/17/2018 2:32 PM
3	Webinars targeting IRBs/ECs	8/16/2018 8:36 PM
4	No.	8/16/2018 7:36 PM
5	No	8/16/2018 5:17 PM
6	Summaries of regulatory guidances.	8/14/2018 3:10 PM
7	Continued education for IRBs appears to be an on going gap.	8/8/2018 2:43 PM
8	No	8/7/2018 2:09 AM
9	Academic institutions	8/6/2018 2:46 PM
10	no	8/6/2018 2:33 PM
11	not right now	8/6/2018 12:09 PM

Q7 From your company's perspective which audience(s) do you feel we should targeting these materials to?

Answered: 17 Skipped: 1



	1	2	3	4	5	TOTAL	SCORE
Study Participants	41.67% 5	33.33% 4	0.00% 0	25.00% 3	0.00% 0	12	3.92
Patient Advocacy Groups	15.38% 2	23.08% 3	38.46% 5	7.69% 1	15.38% 2	13	3.15
IRBs/ECs	35.71% 5	28.57% 4	28.57% 4	7.14% 1	0.00% 0	14	3.93
Company training	28.57% 4	28.57% 4	28.57% 4	7.14% 1	7.14% 1	14	3.64
Conference attendees	10.00% 1	0.00% 0	10.00% 1	30.00% 3	50.00% 5	10	1.90

Q8 If possible, which languages would it be helpful to have certain education materials translated into?

Answered: 15 Skipped: 3

#	RESPONSES	DATE
1	Spanish (LatAm)	8/21/2018 2:18 PM
2	None	8/17/2018 2:32 PM
3	Thinking in the context of global clinical trials: as many as possible, most notably: Spanish, Chinese, French, Japanese, German ...	8/17/2018 1:53 PM
4	Spanish	8/16/2018 8:36 PM
5	Japanese, Chinese, Indian, Spanish	8/16/2018 5:17 PM
6	Spanish	8/14/2018 5:36 PM
7	Japanese, Mandarin	8/14/2018 3:10 PM
8	French, Spanish, Chinese	8/8/2018 2:43 PM
9	Chinese	8/7/2018 2:09 AM
10	English, German, Spanish, Mandarin, French	8/6/2018 4:16 PM
11	? those countries running large trials South America, Eastern Europe, Asia...	8/6/2018 3:29 PM
12	English	8/6/2018 2:46 PM
13	english only	8/6/2018 2:33 PM
14	German, French, Russian, Chinese...	8/6/2018 12:09 PM
15	If we would target patients we would need to provide material in their mother language	8/6/2018 11:41 AM